Russian Pharma Sector Forecast to 2013

The Russian pharma industry is one of the most prolific sectors in the healthcare industry, showing an unprecedented growth of over 17% to generate revenue worth about RUB 538 Billion (US$ 16.14 Billion) in 2009. This high growth rate can be attributed to the development incentives announced by the government for the state drugs segment. The government is also taking the required steps to boost the domestic pharma industry and reduce the dependence on imported products. The Para-pharmaceuticals segment has become one of the leading segments, which has been benefited from the strong young population demand.

According to our new research report “Russian Pharma Sector Forecast to 2013”, the Russian pharma sector is projected to show double-digit growth in near future owing to a rise in investments by the private sector, most importantly the foreign players. Besides, to cater to a large percentage of the population, pharma companies are now shifting their focus towards the research and development projects for manufacturing generic drugs that are less expensive. To understand the direction of the industry, we have done an extensive research and analysis of various segments of the pharma market in the Russian Federation. These segments include: Commercial Drug Segment, State Segment, and the Para-pharmaceutical Segment.

Growth of the Russian pharmaceutical industry is based on the rising health conscious and consequent rise in the healthcare expenditure of the population. Additionally, rising prevalence of diseases and demand for cheaper drugs will be some of the other important drivers for future growth. The overall improvement in the healthcare industry will also pave way for the Russian pharma market to continue its upward trend during the forecast period (2011-2013).

The report provides precise and reliable information, supplemented with statistics, regarding the Russian pharma sector. The report covers leading drugs, segment-wise break up, and information about major therapy areas. It has thoroughly examined current market trends; industrial developments, and competitive landscape to enable clients understand the market structure and its progress in coming years. Forecasts have been done considering the possible impact of recession on the industry.

The report also presents a brief overview of demographics and healthcare profile to adjudge the pharmaceutical market in terms of demands, expenditure, and possible future direction.